Login to Your Account

Other News To Note

Friday, April 29, 2011
PolyMedix Inc., of Radnor, Pa., announced that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity in an in vitro laboratory test against the NDM-1 drug-resistant strain of Klebsiella pneumonia. PMX-30063 also is in a Phase II trial in patients for treatment of acute bacterial skin and skin structure Infections caused by staph bacteria, the company said.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription